CTX130 is an experimental immunotherapy drug that works by targeting a molecule called CD70. Research has shown that CD70 is found at high levels on certain kidney tumours, which makes it a potential target for anti-cancer therapies.
Since this drug is still in the clinical trial phase, it has the placeholder name CTX130 rather than a commercial trade name.
In this trial, patients will have a sample of blood drawn and some of their white blood cells separated from the mixture. These white blood cells will be modified with instructions to seek out and bind to CD70, then transfused back into the patient. In this way, patients’ immune systems may be able to more effectively find and attack tumour cells.
This is a single group study and all patients will receive the experimental therapy: CTX130.
- Any subtype of kidney cancer
- Advanced kidney cancer that cannot be removed by surgery
- No further drug therapies are available or recommended
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreResearch Site 6||Principal InvestigatorDirector: Dr. Matthias Will||LocationToronto, ON||Trial StatusRecruiting|